Edesa Biotech, Inc. (EDSA) |
| 2.765 0.005 (0.18%) 10-23 10:09 |
| Open: | 2.71 |
| High: | 2.9182 |
| Low: | 2.71 |
| Volume: | 4,558 |
| Market Cap: | 27(M) |
| PE Ratio: | -1.64 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 4.27 |
| Resistance 1: | 3.60 |
| Pivot price: | 3.10 |
| Support 1: | 2.52 |
| Support 2: | 2.10 |
| 52w High: | 20.32 |
| 52w Low: | 0.72 |
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Financials
| EPS | -1.650 |
| Book Value | 0.040 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -66.4 |
| Return on Equity (ttm) | -122.9 |
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
